Pfizer withdraws sickle cell disease treatment on risk of complication, death Reuters Sep 26, 2024 Pfizer ends all studies and access to Oxbryta as risks outweigh benefits, based on clinical data
Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare haematology EP News Bureau Aug 9, 2022 Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with…
